Online information event: Improved chances of survival for patients thanks to modern cancer immunotherapy
25.04.2022 18:11
Cancer treatment has made enormous progress in recent years, not least thanks to modern immunotherapies. They have significantly improved the chances of survival compared to former standards such as chemotherapy and are usually associated with a better quality of life. Where does research stand today and for which types of cancer is immunotherapy being used successfully? At an online symposium on May 9th, patients and the interested public can find out about these and other topics and ask experts questions.
The symposium will take place on Monday, May 9, 2022, from 4:00 p.m. to 7:00 p.m. The organizers are the Cluster for Individualized Immune Intervention Ci3 and the Association for Cancer Immunotherapy CIMT in collaboration with Vision Zero eV; the patronage is the National Decade against Cancer. The following topics are on the agenda:
- What is meant by tumor immunotherapy?
- Advances in tumor therapy – integration of new concepts into clinical routine
- Patient Competence – Involving Patients in Clinical Trials
- HPV vaccination against cervical cancer – highly effective and safe
Questions can be directed to the speakers after each topic block via the online platform. These are Professor Dr. Christof von Kalle (Berlin Institute of Health, Charité), Professor Dr. Thomas Kindler (University Center for Tumor Diseases Mainz), Professor Dr. Peter Hillemanns (Hannover Medical School) and Rudolf Hauke, Chairman of the Patient Advisory Board of the German Cancer Research Center.
The patient symposium takes place on the eve of the largest European expert congress for cancer immunotherapy, which takes place from May 10th to 12th in the Rheingoldhalle in Mainz and is organized annually by the Association for Cancer Immunotherapy CIMT.
Participation in the patient symposium is free, but registration is required. Further information and the link to register can be found at https://bit.ly/3Etipyd.
About Ci3
The Cluster for Individualized Immune Intervention (Ci3) brings together the immunotherapeutic and diagnostic expertise available in the Rhine-Main region in the development of new prevention, therapy and diagnostic options. The focus is on the treatment of serious illnesses such as cancer, autoimmune and infectious diseases. The aim of the cluster is to establish the Rhine-Main region at the international forefront in the healthcare industry as a forge for biotechnology-based, individualized medicine with a thematic focus on innovative immunotherapies and diagnostics. More information about Ci3 at www.ci-3.de.
About CIMT
The Association for Cancer Immunotherapy (CIMT) is a non-profit organization dedicated to promoting innovative cancer immunotherapy drugs. In addition to scientific exchange, its goal is cooperation between university institutions, the biotech and pharmaceutical industries and regulatory authorities. It was founded in 2002 with its headquarters in Mainz by renowned scientists and doctors and is coordinated by an international board of directors. More information about CIMT at www.cimt.eu and www.meeting.cimt.eu
About Vision Zero eV
Vision Zero eV is an association of well-known representatives from science, medicine, media, foundations, associations and the research industry. The association sees itself as a think tank and wants to contribute to sustainably improving the prevention and early detection of cancer, to sustainably promote oncological precision diagnostics and innovative therapy concepts and to develop templates for decision-makers in health policy. The aim is to drastically reduce the number of preventable cancer-related deaths, ideally to bring them to zero.